Kyverna Therapeutics Inc (KYTX)

NASDAQ
Currency in USD
4.03
+0.46(+12.89%)
Closed·
After Hours
4.00-0.02(-0.50%)
·
KYTX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
KYTX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.434.06
52 wk Range
1.7811.40
Key Statistics
Edit
Prev. Close
3.57
Open
3.57
Day's Range
3.43-4.06
52 wk Range
1.78-11.4
Volume
826.73K
Average Volume (3m)
445.39K
1-Year Change
-58.17%
Book Value / Share
5.18
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
KYTX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
17.20
Upside
+326.80%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Kyverna Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Kyverna Therapeutics Inc Company Profile

Kyverna Therapeutics, Inc., clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. The company’s lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome and myasthenia gravis that is in phase 2 clinical trial; and for lupus nephritis. It is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing, as well as KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Compare KYTX to Peers and Sector

Metrics to compare
KYTX
Peers
Sector
Relationship
P/E Ratio
−1.2x−2.1x−0.5x
PEG Ratio
−0.02−0.010.00
Price/Book
0.8x1.0x2.6x
Price / LTM Sales
-5.3x3.1x
Upside (Analyst Target)
396.3%381.3%46.1%
Fair Value Upside
Unlock36.4%6.9%Unlock

Analyst Ratings

6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 17.20
(+326.80% Upside)

Earnings

Latest Release
May 14, 2025
EPS / Forecast
-1.03 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

KYTX Income Statement

People Also Watch

2.130
IMAB
+3.90%
2.25
BMGL
-24.24%
3.13
KIDZ
-7.94%
2.85
MCTR
-5.32%

FAQ

What Is the Kyverna Therapeutics (KYTX) Stock Price Today?

The Kyverna Therapeutics stock price today is 4.03

What Stock Exchange Does Kyverna Therapeutics Trade On?

Kyverna Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Kyverna Therapeutics?

The stock symbol for Kyverna Therapeutics is "KYTX."

What Is the Kyverna Therapeutics Market Cap?

As of today, Kyverna Therapeutics market cap is 174.17M.

What Is Kyverna Therapeutics's Earnings Per Share (TTM)?

The Kyverna Therapeutics EPS (TTM) is -3.37.

When Is the Next Kyverna Therapeutics Earnings Date?

Kyverna Therapeutics will release its next earnings report on 17 Aug 2025.

From a Technical Analysis Perspective, Is KYTX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Kyverna Therapeutics Stock Split?

Kyverna Therapeutics has split 0 times.

How Many Employees Does Kyverna Therapeutics Have?

Kyverna Therapeutics has 119 employees.

What is the current trading status of Kyverna Therapeutics (KYTX)?

As of 11 July 2025, Kyverna Therapeutics (KYTX) is trading at a price of 4.03, with a previous close of 3.57. The stock has fluctuated within a day range of 3.43 to 4.06, while its 52-week range spans from 1.78 to 11.40.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.